Benzinga | Oct 27, 2021 04:48PM EDT

Biomarin Pharmaceutical Q3 EPS $(0.20) Beats $(0.25) Estimate, Sales $408.70M Miss $435.32M Estimate

Biomarin Pharmaceutical (NASDAQ:BMRN) reported quarterly losses of $(0.20) per share which beat the analyst consensus estimate of $(0.25) by 20 percent. This is a 104.99 percent decrease over earnings of $4.01 per share from the same period last year. The company reported quarterly sales of $408.70 million which missed the analyst consensus estimate of $435.32 million by 6.12 percent. This is a 14.28 percent decrease over sales of $476.78 million the same period last year.